IPI-Biotherapy for Patients With Metastatic Melanoma Previously Treated With Cytotoxic Drugs.

Trial Profile

IPI-Biotherapy for Patients With Metastatic Melanoma Previously Treated With Cytotoxic Drugs.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2012

At a glance

  • Drugs Ipilimumab (Primary) ; Aldesleukin; Interferon
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jan 2012 Actual initiation date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 25 Jan 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 09 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top